Non-small Cell Lung Cancer (NSCLC) Clinical Trials in New Haven, Connecticut

4 studies are recruiting for non-small cell lung cancer (nsclc) in New Haven, Connecticut right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

    This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma [cutaneous/acral], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric can…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Yale Cancer Center, New Haven, Connecticut
    Locations
    90 in total
    Run by
    Daiichi Sankyo

    See if you can join NCT06172478 on ClinicalTrials.gov

  2. Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

    The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or cetuximab in adults with KRAS G12V-mutant solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Yale Cancer Center, New Haven, Connecticut
    Locations
    9 in total
    Run by
    Revolution Medicines, Inc.

    See if you can join NCT07349537 on ClinicalTrials.gov

  3. Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

    This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alone, and in combination with nivolumab (doublet), nivolumab + …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Exelixis Clinical Site #62, New Haven, Connecticut
    Locations
    122 in total
    Run by
    Exelixis

    See if you can join NCT05176483 on ClinicalTrials.gov

  4. Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

    This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Smilow Cancer Hospital (Yale University), New Haven, Connecticut
    Locations
    17 in total
    Run by
    Revolution Medicines, Inc.

    See if you can join NCT06040541 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.